Trevena, Inc.
Trevena, Inc. develops and commercializes medicines for central nervous system disorders. Lead product candidates include OLINVYK for moderate-to-severe acute pain and TRV734 for moderate-to-severe acute and chronic pain. TRV045 is a novel S1P modulator for managing chronic pain.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Price to book ratio (100.00) is significantly higher than the sector mean (24.44).
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 12.0 |
| EV/EBITDA | - |
| Price/Free Cash Flow' | 6.6 |
| ROIC | 25.3% |
| Net Debt/EBITDA | - |